Rapid and Sustained Eyelid Elevation in Acquired Blepharopto
Oxymetazoline 0.1% is a novel ophthalmic agent for the treatment of acquired blepharoptosis in adults that has been shown to improve upper eyelid elevation and superior visual field deficits. This analysis characterized the rapid onset of upper eyelid elevation with once-daily oxymetazoline 0.1% and durability of this effect over 42 days.

Pooling data from two prospective, randomized, placebo-controlled, phase 3 studies, change in marginal reflex distance 1 (MRD-1) was evaluated at a range of post-instillation time points on treatment days 1, 14, and 42. Onset of effect was assessed beginning at 5 minutes post-administration and through 6 hours at the first two visits. Overall, 203 subjects received oxymetazoline 0.1% and 101 received vehicle.

Results:
--Oxymetazoline 0.1% demonstrated a rapid onset of action on all days evaluated. Mean changes from baseline 5 and 15 minutes post-oxymetazoline 0.1% instillation on day 1 were 0.59 ± 0.72 mm and 0.93 ± 0.81 mm, respectively.

--On day 14, mean changes from baseline 5 and 15 minutes post-oxymetazoline 0.1% instillation were 0.77 ± 0.85 mm and 1.11 ± 0.92 mm, respectively.

--This effect was also observed immediately post-instillation on day 42, where mean increases 5 and 15 minutes post-oxymetazoline 0.1% instillation were 0.86 ± 0.85 mm and 1.04 ± 0.91 mm, respectively.

--Significant improvements vs vehicle were also observed at 2– 6 hours on days 1 and 14.

--At all time points, the proportion of subjects showing a positive response to treatment was more than 15% greater in the oxymetazoline 0.1% group with the largest differences observed 2 and 6 hours post-instillation.

Finally, 0.1% oxymetazoline induced a quick and prolonged elevation of the upper eyelid. This analysis supports 0.1% oxymetazoline as an effective non-surgical treatment for ptosis acquired along with data that demonstrate improved visual field improvement and a favorable safety profile.

Source: https://www.dovepress.com/rapid-and-sustained-eyelid-elevation-in-acquired-blepharoptosis-with-o-peer-reviewed-fulltext-article-OPTH
B●●●u S●●●●a and 1 others like this
Like
Comment
Share